The Journal of Bone and Joint Surgery 81:932-40 (1999)
© 1999 The Journal of Bone and Joint Surgery, Inc.
Comparison of Enoxaparin and Warfarin for the Prevention of Venous Thromboembolic Disease After Total Hip Arthroplasty. Evaluation During Hospitalization and Three Months After Discharge*
CLIFFORD W. COLWELL, JR. M.D. , LA JOLLA,
DENNIS K. COLLIS, M.D., EUGENE, OREGON,
ROLF PAULSON, M.D. , GRAND FORKS, NORTH DAKOTA,
JOHN W. McCUTCHEN, M.D.#, WINTER PARK, FLORIDA,
GREGORY T. BIGLER, M.D.**, LAS VEGAS, NEVADA,
SUSAN LUTZ, R.N. , CHALFONT, PENNSYLVANIA and
MARY E. HARDWICK, M.S.N., LA JOLLA, CALIFORNIA
Background: Venous thromboembolic disease in the form of deep venous thrombosis and pulmonary embolism is a major risk after a total hip arthroplasty. Enoxaparin, a low-molecular-weight heparin, has been shown to reduce the prevalence of deep venous thrombosis after total hip arthroplasty. Warfarin, an orally administered anticoagulant, has been used historically to reduce the risk of deep venous thrombosis after total hip arthroplasty.
Methods: We compared enoxaparin and adjusted-dose warfarin with respect to their safety and their efficacy in the prevention of clinically important venous thromboembolic disease, defined as distal or proximal deep venous thrombosis or pulmonary embolism, or both, during hospitalization after total hip arthroplasty. We also evaluated the prevalence of complications and mortality from venous thromboembolic disease within three months after discharge.
Results: Three thousand and eleven patients at 156 centers were randomly assigned to prophylactic treatment with injection of enoxaparin or oral administration of adjusted-dose warfarin during hospitalization. During the study, fifty-five (3.6 percent) of the 1516 patients who were managed with enoxaparin and fifty-six (3.7 percent) of the 1495 patients who were managed with warfarin had venous thromboembolic disease. Twenty-one patients (0.7 percent), which included four (0.3 percent) of those managed with enoxaparin and seventeen (1.1 percent) of those managed with warfarin (p = 0.0083), had venous thromboembolic disease during hospitalization. After discharge from the hospital, venous thromboembolic disease developed in ninety patients (3.0 percent): fifty-one (3.4 percent) of those managed with enoxaparin and thirty-nine (2.6 percent) of those managed with warfarin. One patient who had been managed with enoxaparin died because of a pulmonary embolism, which was confirmed at autopsy. Three additional patients (one who had been managed with enoxaparin and two who had been managed with warfarin) died, and the deaths were attributed to venous thromboembolic disease; however, no autopsies were performed. Twenty-six patients (0.9 percent) (eighteen managed with enoxaparin and eight managed with warfarin) had clinically important bleeding.
Conclusions: Inpatient programs providing treatment with either enoxaparin (thirty milligrams every twelve hours) or adjusted-dose warfarin for a mean of 7.3 days afforded protection against venous thromboembolic disease, with overall rates of morbidity and mortality of 3.7 and 0.6 percent, respectively, and a very low rate of major bleeding complications (0.9 percent) for three months after total hip arthroplasty. During hospitalization, the patients managed with enoxaparin had a lower rate of venous thromboembolic disease than those managed with adjusted-dose warfarin (p = 0.0083). This benefit was lost after the medication was discontinued, with no difference in the prevalences of venous thromboembolic disease between the two groups at three months after discharge from the hospital.
 CiteULike  Connotea  Del.icio.us  Facebook  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. GANDHI, F. RAZAK, P. TSO, J. R. DAVEY, and N. N. MAHOMED
Metabolic Syndrome and the Incidence of Symptomatic Deep Vein Thrombosis Following Total Knee Arthroplasty
J Rheumatol,
October 1, 2009;
36(10):
2298 - 2301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Hoppe, E. H. Schemitsch, S. Morshed, P. Tornetta III, and M. Bhandari
Hierarchy of Evidence: Where Observational Studies Fit in and Why We Need Them
J. Bone Joint Surg. Am.,
May 1, 2009;
91(Supplement_3):
2 - 9.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Johanson, P. F. Lachiewicz, J. R. Lieberman, P. A. Lotke, J. Parvizi, V. Pellegrini, T. A. Stringer, P. Tornetta III, R. H. Haralson III, and W. C. Watters III
Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty
J. Am. Acad. Ortho. Surg.,
March 1, 2009;
17(3):
183 - 196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Eikelboom, G. Karthikeyan, N. Fagel, and J. Hirsh
American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ: What Are the Implications for Clinicians and Patients?
Chest,
February 1, 2009;
135(2):
513 - 520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Haas, R. L. Barrack, G. Westrich, and P. F. Lachiewicz
Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
J. Bone Joint Surg. Am.,
December 1, 2008;
90(12):
2764 - 2780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F Shorr, E. A Nutescu, E. Farrelly, R. Horblyuk, L. E Happe, and M. Franklin
Postdischarge Oral Versus Injectable Anticoagulation Following Major Orthopedic Surgery
Ann. Pharmacother.,
September 1, 2008;
42(9):
1222 - 1228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
381S - 453S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. D. Dorr, V. Gendelman, A. V. Maheshwari, M. Boutary, Z. Wan, and W. T. Long
Multimodal Thromboprophylaxis for Total Hip and Knee Arthroplasty Based on Risk Assessment
J. Bone Joint Surg. Am.,
December 1, 2007;
89(12):
2648 - 2657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Edelsberg, M. Hagiwara, C. Taneja, and G. Oster
Risk of venous thromboembolism among hospitalized medically ill patients.
Am. J. Health Syst. Pharm.,
October 15, 2006;
63(20 Suppl 6):
S16 - S22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A Nutescu, A. K Wittkowsky, P. P Dobesh, D. W Hawkins, and W. E Dager
Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based Approach
Ann. Pharmacother.,
September 1, 2006;
40(9):
1558 - 1570.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Schiff, S. R. Kahn, I. Shrier, C. Strulovitch, W. Hammouda, E. Cohen, and D. Zukor
Identifying Orthopedic Patients at High Risk for Venous Thromboembolism Despite Thromboprophylaxis
Chest,
November 1, 2005;
128(5):
3364 - 3371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Lieberman and W. K. Hsu
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
J. Bone Joint Surg. Am.,
September 1, 2005;
87(9):
2097 - 2112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J Enyart and R. J Jones
Low-Dose Warfarin for Prevention of Symptomatic Thromboembolism After Orthopedic Surgery
Ann. Pharmacother.,
June 1, 2005;
39(6):
1002 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. K. Chan, I. J Brenkel, and J. Aderinto
The outcome of total hip arthroplasty in diabetes mellitus
The British Journal of Diabetes & Vascular Disease,
May 1, 2005;
5(3):
146 - 149.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. C. Rowlingson and P. B. Hanson
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
Anesth. Analg.,
May 1, 2005;
100(5):
1482 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Agnelli
Prevention of Venous Thromboembolism in Surgical Patients
Circulation,
December 14, 2004;
110(24_suppl_1):
IV-4 - IV-12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. McGuire and P. P. Dobesh
Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism
Journal of Pharmacy Practice,
October 1, 2004;
17(5):
289 - 307.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. A. Hilty
Update in Perioperative Medicine
Ann Intern Med,
September 21, 2004;
141(6):
486 - 486.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Smetana, S. L. Cohn, and V. A. Lawrence
Update in Perioperative Medicine
Ann Intern Med,
September 21, 2004;
141(6):
486 - 487.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Parvizi, M. H. Ereth, and D. G. Lewallen
Thirty-Day Mortality Following Hip Arthroplasty for Acute Fracture
J. Bone Joint Surg. Am.,
September 1, 2004;
86(9):
1983 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, G. F. Pineo, J. A. Heit, D. Bergqvist, M. R. Lassen, C. W. Colwell, and J. G. Ray
Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
338S - 400S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Mosen, C. G. Elliott, M. J. Egger, M. Mundorff, J. Hopkins, R. Patterson, and R. M. Gardner
The Effect of a Computerized Reminder System on the Prevention of Postoperative Venous Thromboembolism
Chest,
May 1, 2004;
125(5):
1635 - 1641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Radl, N. Kastner, C. Aigner, H. Portugaller, H. Schreyer, and R. Windhager
Venous Thrombosis After Hallux Valgus Surgery
J. Bone Joint Surg. Am.,
July 3, 2003;
85(7):
1204 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A Nutescu, R. K Lewis, J. M Finley, and G. T Schumock
Hospital Guidelines for Use of Low-Molecular-Weight Heparins
Ann. Pharmacother.,
July 1, 2003;
37(7):
1072 - 1081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O'Donnell, L.-A. Linkins, C. Kearon, J. Julian, and J. Hirsh
Reduction of Out-of-Hospital Symptomatic Venous Thromboembolism by Extended Thromboprophylaxis With Low-Molecular-Weight Heparin Following Elective Hip Arthroplasty: A Systematic Review
Arch Intern Med,
June 9, 2003;
163(11):
1362 - 1366.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Hyers
Management of Venous Thromboembolism: Past, Present, and Future
Arch Intern Med,
April 14, 2003;
163(7):
759 - 768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B Deitelzweig, G. J Vanscoy, C. S Niccolai, and T. L Rihn
Venous Thromboembolism Prevention with LMWHs in Medical and Orthopedic Surgery Patients
Ann. Pharmacother.,
March 1, 2003;
37(3):
402 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. B. Phillips, J. A. Barrett, E. Losina, N. N. Mahomed, E. A. Lingard, E. Guadagnoli, J. A. Baron, W. H. Harris, R. Poss, and J. N. Katz
Incidence Rates of Dislocation, Pulmonary Embolism, and Deep Infection During the First Six Months After Elective Total Hip Replacement
J. Bone Joint Surg. Am.,
January 17, 2003;
85(1):
20 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Anderson, S. J.-A. Wilson, J. Blundell, D. Petrie, R. Leighton, W. Stanish, D. Alexander, K. S. Robinson, E. Burton, and M. Gross
Comparison of a Nomogramand Physician-Adjusted Dosageof Warfarin for Prophylaxis Against Deep-Vein Thrombosis After Arthroplasty
J. Bone Joint Surg. Am.,
November 12, 2002;
84(11):
1992 - 1997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Samama, M. Vray, J. Barre, J.-N. Fiessinger, N. Rosencher, T. Lecompte, G. Potron, J. Basile, R. Hull, D. Desmichels, et al.
Extended Venous Thromboembolism Prophylaxis After Total Hip Replacement: A Comparison of Low-Molecular-Weight Heparin With Oral Anticoagulant
Arch Intern Med,
October 28, 2002;
162(19):
2191 - 2196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Prandoni, O. Bruchi, P. Sabbion, C. Tanduo, A. Scudeller, C. Sardella, G. Errigo, F. Pietrobelli, G. Maso, and A. Girolami
Prolonged Thromboprophylaxis With Oral Anticoagulants After Total Hip Arthroplasty: A Prospective Controlled Randomized Study
Arch Intern Med,
September 23, 2002;
162(17):
1966 - 1971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Whang and J. R. Lieberman
Low-Molecular-Weight Heparin
J. Am. Acad. Ortho. Surg.,
September 1, 2002;
10(5):
299 - 302.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Douketis, J. W. Eikelboom, D. J. Quinlan, A. R. Willan, and M. A. Crowther
Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement: A Meta-analysis of Prospective Studies Investigating Symptomatic Outcomes
Arch Intern Med,
July 8, 2002;
162(13):
1465 - 1471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Sculco, C. W. Colwell Jr., V. D. Pellegrini Jr., G. H. Westrich, and F. Bottner
Prophylaxis Against Venous Thromboembolic Disease in Patients Having a Total Hip or Knee Arthroplasty
J. Bone Joint Surg. Am.,
March 1, 2002;
84(3):
466 - 477.
[Full Text]
|
|
|
|
|
|
|
R. P. Pitto, H. Hamer, R. Fabiani, M. Radespiel-Troeger, and M. Koessler
Prophylaxis Against Fat and Bone-Marrow Embolism During Total Hip Arthroplasty Reduces the Incidence of Postoperative Deep-Vein Thrombosis : A Controlled, Randomized Clinical Trial
J. Bone Joint Surg. Am.,
January 1, 2002;
84(1):
39 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, M. Butcher, R. F. Brant, W. A. Ghali, D. Bergqvist, et al.
Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review
Ann Intern Med,
November 20, 2001;
135(10):
858 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M T NURMOHAMED and B A C DIJKMANS
Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: a continuing matter of debate
Ann Rheum Dis,
October 1, 2001;
60(10):
905 - 907.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, P. D. Stein, A. F. Mah, S. M. MacIsaac, O. E. Dahl, W. A. Ghali, M. S. Butcher, R. F. Brant, D. Bergqvist, et al.
Timing of Initial Administration of Low-Molecular-Weight Heparin Prophylaxis Against Deep Vein Thrombosis in Patients Following Elective Hip Arthroplasty: A Systematic Review
Arch Intern Med,
September 10, 2001;
161(16):
1952 - 1960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hull, G. Pineo, L. Landow, A. G.G. Turpie, A. S. Gallus, and J. A. Hoek
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis
N. Engl. J. Med.,
July 26, 2001;
345(4):
291 - 292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Bajjoka, R. Hull, G. Pineo, C. Francis, D. Bergqvist, C. Fellenius, A. Mah, and R. Brant
Dalteparin vs Warfarin in Hip Arthroplasty Patients
Arch Intern Med,
March 12, 2001;
161(5):
776 - 777.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Geerts, J. A. Heit, G. P. Clagett, G. F. Pineo, C. W. Colwell, F. A. Anderson Jr., and H. B. Wheeler
Prevention of Venous Thromboembolism
Chest,
January 1, 2001;
119
(2009):
132S - 175S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. White, S. Gettner, J. M. Newman, K. B. Trauner, and P. S. Romano
Predictors of Rehospitalization for Symptomatic Venous Thromboembolism after Total Hip Arthroplasty
N. Engl. J. Med.,
December 14, 2000;
343(24):
1758 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, C. Francis, D. Bergqvist, C. Fellenius, K. Soderberg, A. Holmqvist, M. Mant, R. Dear, B. Baylis, et al.
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients: A Double-blind, Randomized Comparison
Arch Intern Med,
July 24, 2000;
160(14):
2208 - 2215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. SALVATI, V. D. PELLEGRINI, N. E. SHARROCK, P. A. LOTKE, D. W. MURRAY, H. POTTER, and G. H. WESTRICH
Symposium - Recent Advances in Venous Thromboembolic Prophylaxis During and After Total Hip Replacement
J. Bone Joint Surg. Am.,
February 1, 2000;
82(2):
252 - 70.
[Full Text]
|
|
|
|
|
|
|
Enoxaparin vs. Warfarin After Total Hip Arthroplasty
Journal Watch (General),
August 20, 1999;
1999(820):
3 - 3.
[Full Text]
|
|
|
|
